Vol. 10 No. 11-12 (2016): CUAJ December Suppl 7

Published: 2016-12-15

Supplement-Introduction

Sunitinib: 10 years of clinical experience in the treatment of advanced renal cell carcinoma

Anil Kapoor

S235
- PDF

Supplement-Review

First-line treatment options in metastatic renal cell cancer

Anil Kapoor

S236-8
- PDF
Practical first-line management of renal cell carcinoma in a community practice

Henry Conter

S239-41
- PDF
Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Naveen S. Basappa

S242-4
- PDF
Sunitinib side effects as surrogate biomarkers of efficacy

Christian Kollmannsberger

S245-7
- PDF
Sunitinib toxicity management – a practical approach

Sandeep Sehdev

S248-51
- PDF
Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?

Georg A. Bjarnason

S252-5
- PDF
The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma

Daniel Y.C. Heng

S256-8
- PDF